Activities

The Myeloma Unit, led by Prof. Mario Boccadoro, is a referral center for the research on newly diagnosed and relapsed/refractory multiple myeloma. The Unit is involved in the design, development and coordination of national and international multicenter phase I/II/III clinical trials. As for transplant-ineligible patients, Prof. Boccadoro’s team has had a central role in investigating the efficacy and safety of various drug combinations and in evaluating the role of different sequential approaches. In younger patients, the Unit has been a key element to assess the role of high-dose therapy and stem-cell transplantation in the era of novel agents and combinations. In particular, the Myeloma Unit has been playing a fundamental role in the research on minimal residual disease and in the evaluation of new drugs, such as 2nd generation proteasome inhibitors, immunomodulatory drugs and immunotherapeutic agents. All these activities fostered active collaborations with other national and international research groups.

Group

• Prof. Mario Boccadoro (PI)
• Dr. Alessandra Larocca, MD, PhD, tenure track researcher
• Dr. Francesca Maria Gay, MD, PhD, associate professor
• Dr. Roberto Mina, MD, tenure track researcher
• Dr. Mattia D’Agostino, MD, trainee
• Dr. Giusy Cetani, MD, trainee
• Dr. Francesca Bonello, MD, trainee
• Dr. Luca Bertamini, MD, trainee